Company
Raziel Therapeutics
Single session injectable therapy for focal fat reduction.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Raziel offers a revolutionary solution for focal fat-reduction with its proprietary fat-dissolving injectable compound. This one-time, non-surgical treatment caters to both aesthetic and therapeutic needs. Raziel has already signed a commercial licensing agreement for the Chinese market with Fosun Pharma for its first application submental fat, commonly known as double-chin.
Products
- Other
- RZL-012
Loading relationship preview